ArticleCNS neuroscience & therapeutics2026
RAF1 Promotes Gstt1-Mediated Ferroptosis by Promoting KDM1A Recruitment to Facilitate Pilocarpine-Induced Acute Seizure-Associated Neuronal Injury.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSeizures can cause progressive neuronal damage. Our previous studies found that RAF1 mediates vitamin D's alleviation of seizures, but the mechanism by which RAF1 acts in seizures remains unclear.
methodsThe pilocarpine-induced acute seizure-associated neuronal injury (Pilo-ASNI) model and glutamate-treated HT22 cells were used. Behavioral assessments were performed to evaluate seizure severity and latency; histopathological staining was performed to examine neuronal damage and survival; and cellular assays were performed to assess cell viability, cytotoxicity, and DNA damage. Transcriptome sequencing, Co-immunoprecipitation, molecular docking, ChIP-qPCR, and ferroptosis indicators were employed to elucidate the molecular mechanism.
resultsRAF1 expression was markedly upregulated in the Pilo-ASNI model and glutamate-treated HT22 cells. RAF1 knockdown attenuated seizure severity and neuronal damage. Mechanistic studies in HT22 cells revealed that RAF1 inhibited Gstt1 transcription and promoted ferroptosis by promoting KDM1A recruitment and reducing H3K4me2 levels in the promoter region of Gstt1. Disrupting the RAF1-KDM1A interaction could inhibit ferroptosis and alleviate nerve damage, whereas Gstt1 knockdown reverses the protective effect of RAF1 inhibition.
conclusionThis study revealed a RAF1-driven pathway involving KDM1A-mediated epigenetic suppression of Gstt1 and subsequent ferroptosis, which may represent a potential target for neuroprotective intervention in seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.